Press Releases

Solving Kids’ Cancer, The Catherine Elizabeth Blair Memorial Foundation, and Wade’s Army awarded a $136,000 grant to support the novel immunotherapy clinical trial for childhood cancer.  Researchers will use a humanized monoclonal antibody linked to IL2, known as hu14.18-IL2, which specifically targets neuroblastoma tumor cells and binds to them, while the IL2 activates NK cells…

Solving Kids’ Cancer has partnered with Band of Parents, Joining Against Cancer in Kids (J-A-C-K), and Solving Kids’ Cancer Europe, to advance new treatment options for children with neuroblastoma with the launch of a transatlantic  Phase I clinical trial that is open for enrollment in the U.K. and will open soon in the US and Germany…

The childhood cancer community and Solving Kids’ Cancer are grateful to our many champions in Congress, who successfully shepherded this bipartisan bill through both chambers. As a member of the Coalition Against Childhood Cancer (CAC2), we were proud to play a role in advancing and advocating for this legislation alongside CAC2’s advocacy partner coalition, the Alliance for Childhood Cancer, and the entire childhood cancer community.

On Wednesday, May 16th, Solving Kids’ Cancer (SKC), an NYC based nonprofit, held its annual Spring Celebration benefit gala at the Mandarin Oriental New York.  Mikhail “Doctor Mike” Varshavski served as the Master of Ceremonies of the event, which was hosted by Gabby & Gianpaolo, De Felice, Lindy Gad, Angelina Jolin, Jan Planit, Frederique van der Wal, and Bonnie Young and raised over $575,000 for pediatric cancer research.

On Wednesday, May 16th, Solving Kids’ Cancer (SKC) will hold its annual Spring Celebration Benefit Gala. This event, SKC’s signature research fundraiser, draws industry leaders from across the nation to celebrate distinguished individuals who have contributed to the advancement of pediatric cancer therapies. The 2018 honorees are Usman “Oz” Azam, MD, President and CEO of Tmunity Therapeutics and Thomas Gad, Founder and President of Y-mAbs Therapeutics.

A Phase 1 clinical trial leveraging the re-engineered poliovirus is now open for enrollment to children 12 years and older at the Preston Robert Tisch Brain Tumor Center, Duke University Medical Center. After years of following the progress of this promising therapy against adult glioblastoma and working with the research team on behalf of children, Solving Kids’ Cancer teamed up with The Andrew McDonough B+ Foundation to help move this forward in a trial for pediatric brain tumor patients.

Lorlatinib, an investigational drug candidate currently in late-stage clinical development for the treatment of lung cancer may also prove effective for the treatment of the pediatric cancer neuroblastoma. Solving Kids’ Cancer is leading an international effort of like-minded nonprofits to provide nearly $400,000 of collaborative funding for an innovative clinical trial to bring a potentially life-saving therapy to kids.

Solving Kids’ Cancer was the first charity to ever go against the UK healthcare system without a pharmaceutical company involved. As a result, the National Institute for Health and Care Excellence (NICE) recently announced that it has upheld SKC’s appeal against the Institute’s decision not to recommend dinutuximab for treating high-risk neuroblastoma. 

Solving Kids’ Cancer (SKC) together with Wade’s Army announce their joint financial support of this Phase 1 clinical trial to test the safety and efficacy of various investigational drugs that will leverage precision medicine for children with neuroblastoma. This Next Generation Personalized Neuroblastoma Therapy – also known as NEPENTHE (Greek for “medicine for sorrow”) – is the first precision medicine trial for children that will robustly analyze the genomics of their cancer and use combinations of investigational drugs to target specific mutations in their tumors.

The Andrew McDonough B+ Foundation (The B+ Foundation) and Solving Kids’ Cancer (SKC) presented a check for $208,500 to Dr. Matthias Gromeier and Dr. Eric Thompson at the Preston Robert Tisch Brain Tumor Center at Duke, to co-fund an exciting new immunotherapy trial for children with deadly brain tumors.